18F-FDG 符合线路显像在非小细胞肺癌治疗前分期中的价值

目的探讨^18F-脱氧葡萄糖（^18F-FDG）符合线路正电子显像在非小细胞肺癌（NSCLC）治疗前临床分期中的价值。方法39例NSCLC患者在治疗前行^18F-FDG符合线路正电子显像，并进行符合线路显像分期，将符合线路显像分期和CT分期结果进行比较。结果^18F-FDG符合线路显像使18例（46．15％，18／39）的临床总分期发生改变，均为分期升级，其中11例的治疗策略发生改变，由根治性手术治疗变为姑息性放疗或化疗。^18F-FDG符合线路显像对NSCLC总分期的改变主要是通过对N和M分期的改变而实现的。结论^18FF-FDG符合线路显像改变了46．15％（18／39）NSCLC患者的临床分期，影响了28．20％（11／39）的治疗策略。^18F-FDG符合线路显像在NSCLC治疗前分期中有重要的参考价值。

Value of 18F-FDG coincidence SPECT in clinical staging of non-small cell lung cancer before treatment

Objective To evaluate the value of 18F-deoxyglucose ( 18F-FDG) coincidence SPECT in clinical staging of non-small cell lung cancer (NSCLC) before treatment. Methods Thirty-nine patients with NSCLC had been examined by 18F-FDG coincidence SPECT and staged by SPECT before treatment. The results of 18F-FDG coincidence SPECT examination were compared with those of CT. Results The staging was upstaged in 18 patients because of 18F-FDG coincidence SPECT finding. The treatment strategy had been changed in 11 patients with NSCLC. The changing of clinical TNM staging mainly depended on changing of N or M sub-staging by 18F-FDG coincidence SPECT. Conclusion 18F-FDG coincidence SPECT has an important value on treatment strategy in NSCLC patients by changing clinical staging.